Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Gheuens

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The New England Journal of Medicine|November 30, 2012
Multidrug-resistant tuberculosisMel Spigelman, Carolyn Compton, Jan Gheuens, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 22, 2010
New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decadesMel Spigelman, Raymond Woosley, Jan Gheuens
The Journal of Infectious Diseases|March 27, 2012
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the futureChristian Lienhardt, Mario Raviglione, Mel Spigelman, et al.
The Lancet. Infectious Diseases|March 28, 2013
Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for actionWilliam A Wells, Catharina C Boehme, Frank G J Cobelens, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The New England Journal of Medicine|November 30, 2012
Multidrug-resistant tuberculosisMel Spigelman, Carolyn Compton, Jan Gheuens, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 22, 2010
New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decadesMel Spigelman, Raymond Woosley, Jan Gheuens
The Journal of Infectious Diseases|March 27, 2012
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the futureChristian Lienhardt, Mario Raviglione, Mel Spigelman, et al.
The Lancet. Infectious Diseases|March 28, 2013
Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for actionWilliam A Wells, Catharina C Boehme, Frank G J Cobelens, et al.
Pageof 1